Global Health Institute

Global Health Institute

Name of leader and affiliation
Professor Stewart Cole – Global Health Institute, EPFL – UPCOL

Prof. Cole directs the GHI at EPFL, one of the world’s leading Technical Universities, specialized in teaching and research in basic sciences, physical sciences and engineering. He successfully led NM4TB, an integrated project, as part of the 6th framework program and has taken a TB drug candidate from the discovery phase to late preclinical development. Prof. Cole is currently leading another integrated project, MM4TB, as part of FP7. His laboratory has recently developed a simple model for testing drugs against non-growing cells that exploits the 18b strain of M. tuberculosis, a streptomycin (STR)-dependent mutant. It is the only model in existence that can be used in vitro, ex vivo and in animals and thus offers tremendous potential for the discovery of drugs active against latent TB.

Prof. John D. McKinney, Global Health Institute, EPFL

Prof. McKinney heads the Laboratory of Microbiology & Microsystems in the Global Health Institute at EPFL. His lab has pioneered the use of timelapse microfluidic-microscopy for real-time single-cell imaging of mycobacterial responses to antibiotics. The proposed work thus comprises interwoven subprojects focused on microbiology (WP1) and microengineering (WP3). Microbiology-related tasks will be done in our state-of-the-art Biosafety Level 3 facilities. Routine microengineering-related tasks will be done in the in-lab cleanroom facilities; more complex tasks will be done in the state-of-the-art facilities in EPFL’s Center of MicroNanoTechnology



Sorry, no posts found for this author.

Consortium Partners

PreDiCT-TB brings together twenty-one leading European research partners in tuberculosis from both Industry and Academia

View More

The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115337, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.

The communication contained within this site reflects the author’s view and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained therein.